These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 12409574)
1. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Prasad SR; Jhaveri KS; Saini S; Hahn PF; Halpern EF; Sumner JE Radiology; 2002 Nov; 225(2):416-9. PubMed ID: 12409574 [TBL] [Abstract][Full Text] [Related]
2. Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. Prasad SR; Saini S; Sumner JE; Hahn PF; Sahani D; Boland GW J Comput Assist Tomogr; 2003; 27(3):380-4. PubMed ID: 12794603 [TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography. Tran LN; Brown MS; Goldin JG; Yan X; Pais RC; McNitt-Gray MF; Gjertson D; Rogers SR; Aberle DR Acad Radiol; 2004 Dec; 11(12):1355-60. PubMed ID: 15596373 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Venturini M; Durando A; Garrone O; Colozza MA; Contu A; Stevani I; Genta F; Bighin C; Lambiase A; Del Mastro L Cancer; 2003 Mar; 97(5):1174-80. PubMed ID: 12599222 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223 [TBL] [Abstract][Full Text] [Related]
7. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. O'Shaughnessy J Oncology (Williston Park); 2002 Oct; 16(10 Suppl 12):17-22. PubMed ID: 12435175 [TBL] [Abstract][Full Text] [Related]
8. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial. Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ; Oncology; 2004; 67(2):117-22. PubMed ID: 15539915 [TBL] [Abstract][Full Text] [Related]
9. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558 [TBL] [Abstract][Full Text] [Related]
10. Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design? Wright TL; Twelves CJ Eur J Cancer; 2002 Oct; 38(15):1957-60. PubMed ID: 12376198 [No Abstract] [Full Text] [Related]
11. Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast cancer. McDonald F; Miles D Int J Clin Pract; 2003; 57(6):530-4. PubMed ID: 12918893 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C; Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888 [TBL] [Abstract][Full Text] [Related]
13. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Fujimoto-Ouchi K; Tanaka Y; Tominaga T Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360 [TBL] [Abstract][Full Text] [Related]
14. Drug combination approved for advanced breast cancer. FDA Consum; 2002; 36(1):5. PubMed ID: 11881602 [No Abstract] [Full Text] [Related]
15. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M; J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097 [TBL] [Abstract][Full Text] [Related]
17. Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients Before and After Cytotoxic Chemotherapy or Targeted Therapy. He H; Cai C; Charnsangavej C; Theriault RL; Green M; Quraishi MA; Yang WT Can Assoc Radiol J; 2015 Nov; 66(4):356-62. PubMed ID: 26165625 [TBL] [Abstract][Full Text] [Related]
18. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Schwartzberg LS; Arena FP; Mintzer DM; Epperson AL; Walker MS Clin Breast Cancer; 2012 Apr; 12(2):87-93. PubMed ID: 22154117 [TBL] [Abstract][Full Text] [Related]
19. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193 [TBL] [Abstract][Full Text] [Related]
20. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]